Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy

Sangeeta Ray Banerjee (Inventor), Martin G. Pomper (Inventor), Thomas J Meade (Inventor), Ronnie C. Mease (Inventor), Ying Chen (Inventor), Xing Yang (Inventor), Matthew Rotz (Inventor)

Research output: Patent


Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA-specific Ti-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific Ti contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA-targeted imaging in vivo. 86Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.
Original languageEnglish (US)
Patent number10683272
Filing date5/6/15
StatePublished - Jun 16 2020


Dive into the research topics of 'Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy'. Together they form a unique fingerprint.

Cite this